Brett P. Monia
#163,689
Most Influential Person Now
Brett P. Monia's AcademicInfluence.com Rankings
Brett P. Moniabiology Degrees
Biology
#13126
World Rank
#16653
Historical Rank
Molecular Biology
#2181
World Rank
#2215
Historical Rank
Biochemistry
#2272
World Rank
#2419
Historical Rank
Download Badge
Biology
Brett P. Monia's Degrees
- PhD Molecular Biology University of California, San Diego
- Bachelors Biochemistry University of California, San Diego
Why Is Brett P. Monia Influential?
(Suggest an Edit or Addition)Brett P. Monia's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. (2006) (2009)
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. (2004) (1821)
- Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis (2007) (916)
- Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. (1993) (624)
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis (2018) (553)
- Antisense oligonucleotide therapy for neurodegenerative disease. (2006) (450)
- Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. (2002) (417)
- Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. (2006) (412)
- Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease (2007) (403)
- Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice (2014) (403)
- Factor XI antisense oligonucleotide for prevention of venous thrombosis. (2014) (398)
- Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant (1994) (390)
- PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice (2002) (380)
- Role of resistin in diet-induced hepatic insulin resistance. (2004) (357)
- Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (2014) (348)
- Suppression of Diacylglycerol Acyltransferase-2 (DGAT2), but Not DGAT1, with Antisense Oligonucleotides Reverses Diet-induced Hepatic Steatosis and Insulin Resistance* (2007) (330)
- Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals (2006) (324)
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer (2015) (303)
- Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice Published, JLR Papers in Press, January 22, 2007. (2007) (289)
- Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. (2006) (283)
- Antisense transcripts are targets for activating small RNAs (2008) (280)
- Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway (1996) (280)
- Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. (2001) (268)
- Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice (2005) (263)
- Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. (2007) (261)
- Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. (2005) (245)
- Protein Kinase C-ζ Mediates Angiotensin II Activation of ERK1/2 in Vascular Smooth Muscle Cells* (1997) (225)
- Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. (1992) (221)
- Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. (2002) (220)
- Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. (2006) (217)
- Therapeutic potential for microRNAs. (2007) (215)
- Implication of RNA structure on antisense oligonucleotide hybridization kinetics. (1992) (209)
- Antisense Research and Application (1998) (204)
- Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. (2004) (201)
- Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. (2011) (194)
- Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. (2013) (193)
- Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. (2004) (192)
- SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats (2009) (182)
- The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. (2009) (180)
- Targeting Foxo1 in Mice Using Antisense Oligonucleotide Improves Hepatic and Peripheral Insulin Action (2006) (177)
- Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. (2010) (173)
- Mitogen-activated Protein (MAP) Kinase Is Regulated by the MAP Kinase Phosphatase (MKP-1) in Vascular Smooth Muscle Cells (1995) (168)
- Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. (1995) (167)
- Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. (2002) (163)
- Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia. (1999) (161)
- Second Generation of Antisense Oligonucleotides: From Nuclease Resistance to Biological Efficacy in Animals (1996) (152)
- Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. (2014) (148)
- Nuclease Resistance and Antisense Activity of Modified Oligonucleotides Targeted to Ha-ras* (1996) (141)
- Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. (2001) (138)
- Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. (1996) (135)
- STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. (2018) (134)
- Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy (2012) (133)
- Inhibition of c-Jun N-terminal kinase 1, but not c-Jun N-terminal kinase 2, suppresses apoptosis induced by ischemia/reoxygenation in rat cardiac myocytes. (2001) (131)
- Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). (1999) (128)
- Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. (2014) (128)
- Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. (2005) (126)
- Ubiquitin fusion augments the yield of cloned gene products in Escherichia coli. (1989) (126)
- Relaxin positively regulates matrix metalloproteinase expression in human lower uterine segment fibroblasts using a tyrosine kinase signaling pathway. (2001) (123)
- Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. (2001) (118)
- Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in Primates (2013) (115)
- Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes. (2007) (113)
- 2'-O-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides. (1996) (112)
- Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS (2017) (112)
- Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth (2015) (108)
- Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides (2016) (108)
- Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. (2002) (107)
- Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. (2003) (106)
- Novel mechanisms for antisense-mediated regulation of gene expression. (1999) (98)
- The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2 (2012) (97)
- Increasing gene expression in yeast by fusion to ubiquitin. (1989) (95)
- Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. (2007) (95)
- Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. (2009) (93)
- Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. (2013) (92)
- A Phase I trial of h‐ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma (2001) (92)
- Targeted delivery of antisense oligonucleotides to pancreatic β-cells (2018) (91)
- Diacylglycerol acyltranferase 1 anti‐sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis (2007) (91)
- Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. (1996) (91)
- Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. (2004) (89)
- Loss of PTEN is associated with progression to androgen independence (2006) (88)
- Bcl‐XL is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy (2002) (85)
- Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension (2017) (84)
- Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. (2012) (82)
- Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen. (2015) (81)
- Anti-Inflammatory Activity of Inhaled IL-4 Receptor-α Antisense Oligonucleotide in Mice (2007) (80)
- c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). (1999) (80)
- Regulation of 5-lipoxygenase and 5-lipoxygenase-activating protein expression in HL-60 cells. (1993) (76)
- Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. (2003) (73)
- Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. (2011) (72)
- Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious mice. (2005) (72)
- Characterization and modulation of immune stimulation by modified oligonucleotides. (1997) (71)
- Allele-Specific Inhibition of Rhodopsin With an Antisense Oligonucleotide Slows Photoreceptor Cell Degeneration. (2015) (71)
- Antisense Oligonucleotides Demonstrate a Dominant Role of c-Ki-RAS Proteins in Regulating the Proliferation of Diploid Human Fibroblasts* (1996) (70)
- Coagulation factor XI as a novel target for antithrombotic treatment (2010) (69)
- Reduction of Low Molecular Weight Protein-tyrosine Phosphatase Expression Improves Hyperglycemia and Insulin Sensitivity in Obese Mice* (2007) (68)
- Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice (2017) (68)
- Inhibition of Antigen-Induced Eosinophilia and Late Phase Airway Hyperresponsiveness by an IL-5 Antisense Oligonucleotide in Mouse Models of Asthma (2000) (67)
- Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. (1997) (67)
- Elucidating cell signaling mechanisms using antisense technology. (2000) (66)
- Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. (2013) (65)
- Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice. (2014) (65)
- Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys. (2009) (64)
- Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia (2016) (64)
- Mcl-1 Is a Novel Therapeutic Target for Human Sarcoma (2004) (64)
- Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer (2001) (63)
- Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo (2011) (63)
- Gene synthesis, expression, structures, and functional activities of site-specific mutants of ubiquitin. (1987) (61)
- An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. (2002) (61)
- Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines (2005) (60)
- Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice. (2017) (58)
- Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. (1999) (57)
- Bcl-2 sustains increased mucous and epithelial cell numbers in metaplastic airway epithelium. (2005) (56)
- Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing. (2000) (56)
- Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. (1997) (55)
- Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing. (2004) (54)
- Inhibition of telomerase by 2'-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. (2001) (53)
- Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. (2007) (53)
- Gene synthesis, expression, and processing of human ubiquitin carboxyl extension proteins. (1989) (52)
- Factor XI Regulates Pathological Thrombus Formation on Acutely Ruptured Atherosclerotic Plaques (2014) (51)
- A Role for c-Raf Kinase and Ha-Ras in Cytokine-mediated Induction of Cell Adhesion Molecules* (1998) (51)
- Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice. (2019) (50)
- Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation. (1997) (50)
- An oral antisense oligonucleotide for PCSK9 inhibition (2021) (49)
- Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides. (2008) (48)
- Distinct roles of JNKs/p38 MAP kinase and ERKs in apoptosis and survival of HCD-57 cells induced by withdrawal or addition of erythropoietin. (1999) (47)
- Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. (2006) (46)
- Transthyretin Antisense Oligonucleotides Lower Circulating RBP4 Levels and Improve Insulin Sensitivity in Obese Mice (2014) (45)
- Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment (2010) (45)
- In vivo suppression of Bcl‐XL expression facilitates chemotherapy‐induced leukaemia cell death in a SCID/NOD‐Hu model (2001) (44)
- Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis (2014) (44)
- Interleukin‐2 family cytokines stimulate phosphorylation of the Pro‐Ser‐Pro motif of Stat5 transcription factors in human T cells: resistance to suppression of multiple serine kinase pathways (2002) (43)
- Nonsense Mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR. (2019) (43)
- Antisense oligodeoxynucleotides for urokinase‐plasminogen activator receptor have anti‐invasive and anti‐proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice (2004) (43)
- Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA. (2007) (43)
- Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival. (2004) (43)
- Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. (2015) (41)
- Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. (2015) (41)
- Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. (1999) (41)
- Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice. (2005) (41)
- Antisense Oligonucleotides to poly(ADP-ribose) Polymerase-2 Ameliorate Colitis in Interleukin-10-Deficient Mice (2002) (41)
- ISIS-FXIRx, A Novel and Specific Antisense Inhibitor of Factor XI, Caused Significant Reduction in FXI Antigen and Activity and Increased aPTT without Causing Bleeding in Healthy Volunteers (2011) (41)
- Thrombin signaling promotes pancreatic adenocarcinoma through PAR-1-dependent immune evasion. (2019) (40)
- Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. (2002) (40)
- Selective killing of cancer cells based on loss of heterozygosity and normal variation in the human genome: a new paradigm for anticancer drug therapy. (1999) (40)
- Inhaled CD86 Antisense Oligonucleotide Suppresses Pulmonary Inflammation and Airway Hyper-Responsiveness in Allergic Mice (2007) (39)
- Inhibition of hypoxia/reoxygenation-induced apoptosis by an antisense oligonucleotide targeted to JNK1 in human kidney cells. (2000) (38)
- Reducing dynamin 2 (DNM2) rescues DNM2-related dominant centronuclear myopathy (2018) (38)
- Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations (2018) (37)
- Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid. (2005) (37)
- Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death. (2005) (37)
- Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. (1998) (37)
- Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs. (2002) (37)
- Telomerase reverse transcriptase (hTERT) mRNA and telomerase RNA (hTR) as targets for downregulation of telomerase activity. (2004) (36)
- Bcl-xL Antisense Oligonucleotides Chemosensitize Human Glioblastoma Cells (2002) (36)
- Role of Ras isoforms in the stimulated proliferation of human renal fibroblasts in primary culture. (2000) (35)
- Remarkable enhancement of binding affinity of Heterocycle-modified DNA to DNA and RNA. Synthesis, characterization and biophysical evaluation of N2-imidazolylpropylguanine and N2-imidazolylpropyl-2-aminoadenine modified oligonucleotides (1994) (34)
- Antisense oligonucleotide therapy for TTR amyloidosis (2011) (33)
- Thrombin drives tumorigenesis in colitis-associated colon cancer. (2014) (33)
- Multiple (alpha-NH-ubiquitin)protein endoproteases in cells. (1989) (32)
- PKCepsilon plays a causal role in acute ethanol-induced steatosis. (2009) (32)
- Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12. (2013) (32)
- Pharmacology of antisense therapeutic agents : cancer and inflamination. (1996) (32)
- Biophysical and antisense properties of oligodeoxynucleotides containing 7-propynyl-, 7-iodo- and 7-cyano-7-deaza-2-amino-2'-deoxyadenosines. (1998) (31)
- Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice. (2008) (30)
- In Vitro and In Vivo Inhibition of Interleukin (IL)-5–Mediated Eosinopoiesis by Murine IL-5R α Antisense Oligonucleotide (2001) (30)
- STAT3 regulates the growth and immunoglobulin production of BCL(1) B cell lymphoma through control of cell cycle progression. (2000) (29)
- Antisense Oligonucleotide Targeting of Raf-1 (2004) (29)
- Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data (2020) (29)
- Peripheral Reduction of FGFR4 with Antisense Oligonucleotides Increases Metabolic Rate and Lowers Adiposity in Diet-Induced Obese Mice (2013) (29)
- Discovery and analysis of antisense oligonucleotide activity in cell culture. (2001) (29)
- Bcl-xL antisense oligonucleotides radiosensitise colon cancer cells (2003) (27)
- Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells (2006) (26)
- Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization (2003) (26)
- Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissue. (2010) (25)
- Knockdown of the gene encoding Drosophila tribbles homologue 3 (Trib3) improves insulin sensitivity through peroxisome proliferator-activated receptor-γ (PPAR-γ) activation in a rat model of insulin resistance (2011) (25)
- Metallothionein turnover in mammalian cells. Implications in metal toxicity. (1986) (24)
- Evidence of a role for Ki-Ras in the stimulated proliferation of renal fibroblasts. (1999) (24)
- Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis (2011) (24)
- Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice. (2016) (23)
- Telomerase inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2'-O-methoxyethyl oligonucleotides. (2002) (22)
- Antisense Oligonucleotides Targeting Jagged 1 Reduce House Dust Mite-Induced Goblet Cell Metaplasia in the Adult Murine Lung. (2020) (21)
- Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis. (2019) (21)
- Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo. (2003) (21)
- Steric Inhibition of 5′ UTR Regulatory Elements Results in Upregulation of Human CFTR (2019) (21)
- Antisense knockdown of Kras inhibits fibrosis in a rat model of unilateral ureteric obstruction. (2012) (21)
- First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. (1997) (20)
- First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase. (1997) (20)
- Partial Hepatectomy Induced Long Noncoding RNA Inhibits Hepatocyte Proliferation during Liver Regeneration (2015) (20)
- Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease (2014) (20)
- Inhibition of spinal cytosolic phospholipase A2 expression by an antisense oligonucleotide attenuates tissue injury-induced hyperalgesia (2008) (20)
- Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia. (2020) (19)
- Regulation of Lipoprotein Lipase by Protein Kinase Cα in 3T3-F442A Adipocytes* (2002) (19)
- Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low‐density lipoprotein receptor‐deficient mice (2021) (19)
- Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide (2016) (18)
- Translational regulation of lipoprotein lipase in adipocytes: depletion of cellular protein kinase Calpha activates binding of the C subunit of protein kinase A to the 3'-untranslated region of the lipoprotein lipase mRNA. (2008) (17)
- Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells (2016) (17)
- Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial (2018) (17)
- A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. (2013) (17)
- Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression. (2008) (16)
- Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice. (2019) (16)
- Induction of metallothionein is correlated with resistance to auranofin, a gold compound, in Chinese hamster ovary cells. (1987) (15)
- IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production (2019) (15)
- A human ubiquitin carboxyl extension protein functions in yeast. (1990) (15)
- Antisense oligonucleotide targeting of mRNAs encoding ENaC subunits α, β, and γ improves cystic fibrosis-like disease in mice. (2019) (15)
- Specific Reduction of Hepatic Glucose 6-Phosphate Transporter-1 Ameliorates Diabetes while Avoiding Complications of Glycogen Storage Disease* (2007) (14)
- Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations (2019) (14)
- Molecular and cellular characterization of baboon C-Raf as a target for antiproliferative effects of antisense oligonucleotides. (1997) (14)
- Effects of antisense oligonucleotide-mediated depletion of tumor necrosis factor (TNF) receptor 1-associated death domain protein on TNF-induced gene expression. (2004) (14)
- Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (2021) (14)
- Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications. (1998) (13)
- Role for Cela1 in Postnatal Lung Remodeling and Alpha‐1 Antitrypsin‐Deficient Emphysema (2018) (12)
- Evaluation of biological role of c-Jun N-terminal kinase using an antisense approach. (2000) (12)
- Treatment of transthyretin cardiomyopathy with a TTR-specific antisense oligonucleotide (IONIS-TTRRx) (2017) (12)
- Studies on the Structure and Function of Ubiquitin (1990) (10)
- Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis (2020) (9)
- Immunogenicity Assessment of Inotersen, a 2'-O-(2-Methoxyethyl) Antisense Oligonucleotide in Animals and Humans: Effect on Pharmacokinetics, Pharmacodynamics, and Safety. (2020) (9)
- Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference (2017) (9)
- Use of antisense oligonucleotides to correct the splicing error in ISCU myopathy patient cell lines. (2016) (9)
- Genomic Analysis of wig-1 Pathways (2012) (9)
- Abstract 2713: Discovery and characterization of AZD8701, a high affinity antisense oligonucleotide targeting FOXP3 to relieve immunosuppression in cancer (2019) (9)
- Regulation of lipoprotein lipase by protein kinase C alpha in 3T3-F442A adipocytes. (2002) (9)
- In vitro and in vivo inhibition of interleukin (IL)-5-mediated eosinopoiesis by murine IL-5Ralpha antisense oligonucleotide. (2001) (8)
- Pharmacology of 2'-O-(2-Methoxy)ethyl- Modified Antisense Oligonucleotides (2001) (8)
- Chromosomal mapping of the ubiquitin gene family in Saccharomyces cerevisiae by pulsed field gel electrophoresis. (1989) (7)
- Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) (2019) (7)
- Identification of REST-regulated genes and pathways using a REST-targeted antisense approach. (2013) (7)
- Phase 1 Investigation of a Ligand-Conjugated Antisense Oligonucleotide with Increased Potency for the Treatment of Transthyretin Amyloidosis (2019) (7)
- Targeting TMPRSS6 Using Antisense Technology for the Treatment of Beta-Thalassemia (2015) (6)
- Reversing Antisense Oligonucleotide Activity with a Sense Oligonucleotide Antidote: Proof of Concept Targeting Prothrombin. (2015) (6)
- CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway (2022) (6)
- In Vitro and In Vivo Effects of SerpinA1 on the Modulation of Transthyretin Proteolysis (2021) (6)
- Pharmacological Activity of Antisense Oligonucleotides in Animal Models of Disease (1998) (6)
- Systemic Pharmacodynamic Efficacy of a Complement Factor B Antisense Oligonucleotide in Preclinical and Phase 1 Clinical Studies (2017) (6)
- Transmembrane Protease, Serine 6 (TMPRSS6) Antisense Oligonucleotide (IONIS-TMPRSS6-LRX) Reduces Plasma Iron Levels of Healthy Volunteers in a Phase 1 Clinical Study (2018) (6)
- SERPINA1 modulates expression of amyloidogenic transthyretin. (2020) (6)
- Synthesis, Biophysical and Biological Evaluations of Novel Antisense Oligonucleosides Containing Dephosphono-Internucleosidic Linkages (1995) (5)
- Developing a Galnac-Conjugated TMPRSS6 Antisense Therapy for the Treatment of β-Thalassemia (2016) (5)
- Abstract 716: ISIS 401025, a Second Generation Antisense Oligonucleotide Targeting Prothrombin, Inhibits Plasma Prothrombin Level and Promotes Anticoagulation in Mice (2007) (5)
- Protein Tyrosine Phosphatase 1B Reduction Regulates Adiposity and Expression of Genes Involved in (2002) (5)
- Antisense inhibition of membrane-bound human interleukin-5 receptor-alpha chain does not affect soluble receptor expression and induces apoptosis in TF-1 cells. (2000) (5)
- Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis (2015) (5)
- Abstract LB-227: Preclinical pharmacology and clinical efficacy of AZD9150 (ISIS-STAT3Rx), a potent next-generation antisense oligonucleotide inhibitor of STAT3 (2014) (5)
- Allele specific knock-down of human P23H rhodopsin mRNA and prevention of retinal degeneration in humanized P23H rhodopsin knock-in mouse, following treatment with an intravitreal GAPmer antisense oligonucleotide (QR-1123) (2019) (5)
- Optimization of Second-Generation Antisense Drugs: Going Beyond Generation 2.0 (2007) (4)
- Antisense therapy for cancer. (1998) (4)
- Cellular and molecular pharmacology of auranofin and related gold complexes. (1986) (4)
- Systematic Evaluation of Coagulation Factors as Targets for Anti-Thrombotic Therapy Using Antisense Technology. (2009) (4)
- Targeting Hepcidin with Antisense Oligonucletides Improves Anemia Endpoints in Mice. (2006) (4)
- A Phase 3 Study to Evaluate ISIS-TTRRx in Patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP): Study Design and Baseline Demographics (S50.006) (2015) (3)
- Abstract 13307: An Oral Antisense Oligonucleotide for PCSK9 Inhibition in Humans (2020) (3)
- The ISIS-TTRRx-CS2 phase 3 study in patients with familial amyloid polyneuropathy: Baseline results of the first 100 patients for the NIS, NIS+7 and mNIS+7 using different methods of scoring: identification of consistencies and key differences (2015) (3)
- oligonucleotide in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. (2018) (3)
- Pharmacological Characterization and Structure Activity Relationship of FXI Antisense Oligonucleotides in Cynomolgus Monkeys. (2009) (3)
- Sex-specific differences in emphysema using a murine antisense oligonucleotide model of α-1 antitrypsin deficiency. (2019) (3)
- Cholesterol Conjugated Uniform and Gapmer Phosphorothioate Oligonucleotides Targeted Against PKC-α and C-raf Gene Expression (1997) (3)
- INOTERSEN IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY AND CARDIOMYOPATHY: RESULTS OF THE PHASE 3 STUDY NEURO-TTR (2018) (3)
- A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy (2015) (3)
- Target TMPRSS6 for the Treatment of Hereditary Hemochromatosis (2011) (2)
- Evaluation of the Antihemostatic and Antithrombotic Effects of Lowering Coagulation Factor VII Levels in a Non-human Primate (2020) (2)
- Knockdown of Z Mutant Alpha-1 Antitrypsin In Vivo Using Modified DNA Antisense Oligonucleotides. (2017) (2)
- Cross-Linking Agents Ionizing Radiation , Bleomycin , and Etoposide but not DNA Messenger RNA Sensitizes M 059 K Malignant Glioma Cells to An Antisense Oligonucleotide Targeted to Human Ku 86 Updated (2002) (2)
- Antisense as a Novel Therapy for Cancer (2000) (2)
- Tu1724 In Vitro Study of the 2nd-Generation Antisense Oligonucleotide ISIS-TTRRX in Familial Amyloid Polyneuropathy-Specific Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cells (2016) (2)
- Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations (2018) (2)
- Combination of Tmprss6-ASO and the Iron Chelator Deferiprone Improves Erythropoiesis and Reduces Iron Overload in a Mouse Model of Beta-Thalassemia (2014) (2)
- Open Label Extension of the Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis (P1.324) (2018) (2)
- Abstract LB-317: Potentin vivopharmacology of AZD9150, a next-generation, constrained ethyl-modified antisense oligonucleotide targeting STAT3 in multiple preclinical cancer models. (2013) (2)
- Antisense oligonucleotide‐mediated knockdown of Mpzl3 attenuates the negative metabolic effects of diet‐induced obesity in mice (2021) (2)
- Thrombin and Factor XII Drive Prostate Tumor Growth In Vivo (2015) (1)
- Remarkable Enhancement of Binding Affinity of Heterocycle-Modified DNA to DNA and RNA. Synthesis, Characterization and Biophysical Evaluation of N2-Imidazolylpropylguanine and N2-Imidazolylpropyl-2-aminoadenine Modified Oligonucleotides. (1994) (1)
- Leukotriene Receptors and Mechanisms of Signal Transduction (1991) (1)
- Abstract B23: Selective inhibition of a long non-coding RNA (lncRNA), MALAT1 by antisense oligonucleotides results in significant anti-tumor effects in a variety of preclinical cancer models (2012) (1)
- Arterial thrombosis is accelerated in histidine-rich glycoprotein deficient mice (2015) (1)
- Biologic consequences of androgen receptor (AR) activity in MDV3100-resistant LNCaP cells and dependence on AR full length. (2014) (1)
- Thrombin-Thrombomodulin Interactions Are An Important Determinant of Metastatic Potential (2010) (1)
- The role of transforming growth factor-β in carcinogenesis (2005) (1)
- Burden of Hereditary Transthyretin Amyloidosis With Polyneuropathy in Patients Enrolled in the Phase 3 Study NEURO-TTR (P1.331) (2018) (1)
- Abstract C136: Exploring the functional contribution of STAT3 activity in tumor and tumor-associated stromal cells with species-selective generation 2.5 antisense oligonucleotides in preclinical cancer models. (2011) (1)
- CHAPTER 4. Antisense Technology: Liver Targeting and Beyond for Drug Discovery (2019) (1)
- Abstract A259: Characterization of next generation (Gen2.5) KRAS antisense inhibitors in NSCLC, PDAC, and CRC models. (2013) (1)
- Pharmacodynamic efficacy of IONIS-FB-LRX, a complement factor B antisense oligonucleotide, in a phase 1 clinical study (2018) (1)
- Regulation Of Hematopoietic Stem Cell Trafficking By The Coagulation Pathway (2013) (1)
- ISIS-FXIRx, a Potent Antisense Inhibitor of Factor XI, Suppresses FXI Activity and Elevates Aptt without Increased Risk of Bleeding in Cynomolgus Monkeys Following 13 Weeks of Treatment (2011) (1)
- Target TMPRSS6 Using Antisense Technology for the Treatment of Hereditary Hemochromatosis and β-Thalassemia (2012) (1)
- The Role of MPZL3 as a Metabolic Regulator in Ovarian Cancer (2017) (1)
- Evaluation of modifications of nis+7 score in oligonucleotide trials in ttr fap (2015) (1)
- Abstract 5376: Antisense oligonucleotide targeting insulin-like growth factor-1 receptor (IGF-1R) enhances paclitaxel sensitivity in a castrate-resistant and paclitaxel-resistant prostate cancer model (2010) (1)
- Abstract 13913: Single Dose Safety, Pharmacokinetics, and Pharmacodynamics of a Potent PCSK9 Synthesis Inhibitor, AZD8233, in Subjects With Elevated Ldl Cholesterol (2020) (1)
- Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation (2022) (1)
- 593 Antisense Oligonucleotide Reduction of Mutant Alpha-1 Antitrypsin Protein for the Treatment of Alpha-1 Antitrypsin Liver Disease (2012) (0)
- Antisense Strategies to Specifically Deplete Levels of Factors II, VII and IX in Mice To Assess Their Potential as Targets for Anticoagulation. (2007) (0)
- Platelet-Localized FXI Promotes a Glycoprotein Ib Alpha Dependent Feedback Loop in Arterial Hypertension and Vascular Inflammation (2015) (0)
- Compositions and their uses targeting diacylglycerol acyltransferase 1 (2007) (0)
- FXII Antisense Oligonucleotide Mediated Depletion Results In Effective Anticoagulation without Bleeding Risk. (2010) (0)
- Effect of generation 2.5 antisense inhibitor of androgen receptor on MDV3100-resistant prostate cancer cell growth in vitro and in vivo. (2013) (0)
- Abstract LB-B20: High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T cells and produce anti-tumor effects in syngeneic tumor models (2018) (0)
- Prevention of photoreceptor cell degeneration in P23H rats after allele-specific knockdown of mutant Rhodopsin RNA expression using antisense oligonucleotide (ASO) treatment (2014) (0)
- Thrombin Supports Colitis and Colitis-Associated Cancer Pathogenesis (2011) (0)
- 234 TARGETING STAT5 DEGRADES ANDROGEN RECEPTOR VIA THE PROTEASOME AND PROLONGS TIME TO TUMOR PROGRESSION POST CASTRATION IN VIVO (2010) (0)
- Patchy sugar-modified oligonucleotides (1997) (0)
- P010. Evaluation of the Efficacy and Safety of AKCEA-TTR-LRx (ION-682884) in Patients with Transthyretin-mediated Amyloid Cardiomyopathy: The CARDIO-TTRansform Study (2021) (0)
- Lack of Substantial Antithrombotic Effect of Low Circulating Coagulation Factor VII Levels in a Baboon Model of Acute Vascular Graft Thrombosis (2014) (0)
- TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis (2023) (0)
- Role of Chymotrypsin-like Elastase 1 in Lung Physiology and in α1-Antitrypsin Deficiency (2017) (0)
- Metallothionein turnover in mammalian cell lines: implications in drug resistance (1986) (0)
- Abstract A73: Antisense oligonucleotides targeting ENO2 have selective anti-proliferative effects in glioblastoma cell with 1p36 genomic loss (2015) (0)
- The modulation factor of 11 expression (2009) (0)
- P1.5: AGE AND HYPERTENSION STRONGLY REDUCE AORTIC VISCO-ELASTIC PROPERTIES IN RATS AT BASAL AND MATCHED BLOOD PRESSURE LEVELS (0)
- Oligonucleotides modifies par derivation en 2 (1992) (0)
- Amelioration of Photoreceptor Degeneration in a Mouse Model of P23H ADRP Using an Antisense Oligonucleotide (ASO) (2015) (0)
- Patent Number : ( 45 ) Date of Patent : 5 , 576 , 208 Nov . 19 , 1996 (2017) (0)
- Carbohydrate modified lucke-like oligonucleotides (1997) (0)
- Thrombin Drives Colorectal Cancer Pathogenesis at the Level of Primary Tumor Growth, Tumor Invasion and Metastasis (2014) (0)
- Compounds and methods for modulating expression PCSK9 (2007) (0)
- Sugar-modified oligonucleotides open. (1997) (0)
- 196 Characterization of Generation 2.5 Androgen Receptor Antisense Oligonucleotides Targeting Full Length AR and AR Splice Variants (2012) (0)
- Decreased adiposity and improved insulin sensitivity in obese mice after suppression of hepatic and adipose tissue FGFR4 expression (2008) (0)
- Modulation de l'expression du facteur 7 (2008) (0)
- Inotersen Improves Norfolk Quality of Life-Diabetic Neuropathy Measures in Patients With Hereditary Transthyretin Amyloidosis with Polyneuropathy in the Phase 3 Study NEURO-TTR (S5.006) (2018) (0)
- MP24-04 CO-TARGETING CLUSTERIN AND THE ANDROGEN RECEPTOR WITH OGX-011 AND AN AR ANTISENSE SYNERGISTICALLY ENHANCES ACTIVITY OF ENZALUTAMIDE-RESISTANT PROSTATE CANCER (2014) (0)
- Results Inhibition of FXI With aXIMab : Effects on Thrombosis in the Baboon Model (2013) (0)
- Inhibiting Mcl-1 with an antisense oligonucleotide induces cell death in acute myeloid leukemia cells (2006) (0)
- THROMBOSIS AND HEMOSTASIS Arterial thrombosis is accelerated in mice de fi cient in histidine-rich glycoprotein (2015) (0)
- WS01.1 Identification of a human antisense inhibitor against ENaC for the treatment of cystic fibrosis (2017) (0)
- Mouse Models of Asthma by an IL-5 Antisense Oligonucleotide in and Late Phase Airway Hyperresponsiveness Inhibition of Antigen-Induced Eosinophilia (2000) (0)
- Antisense OLIGONUKLEOTIDMODULATION OF GENE EXPRESSION raf (1995) (0)
- 727 ANTISENSE OLIGONUCLEOTIDE TARGETING INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR ENHANCES PACLITAXEL SENSITIVITY IN A PACLITAXEL- RESISTANT PROSTATE CANCER MODEL (2011) (0)
- Safety and Efficacy of Inotersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NEURO-TTR) (N2.001) (2018) (0)
- PTEN Key to Herceptin Response in Her2-Positive Breast Cancer (2004) (0)
- Advances in Brief Inhibition of Hepatic Endothelial E-Selectin Expression by C-raf Antisense Oligonucleotides Blocks Colorectal Carcinoma Liver Metastasis 1 (2002) (0)
- LPA-induced renal epithelial cell proliferation is N-Ras dependent and MAP kinase independent (2000) (0)
- A Sense Oligonucleotide Specifically Reverses the Prothrombin Depletion and Anticoagulation Caused by ISIS 401025, an Antisense Oligonucleotide Targeting Prothrombin RNA in Mice. (2007) (0)
- Abstract LB-302: Inhibition of STAT3 following systemic delivery of STAT3 antisense oligonucleotide results in target inhibition in tumor and tumor-associated stromal cells and dramatic reduction in circulating pro-tumorigenic cytokines (2011) (0)
- Combination of FXI Antisense Oligonucleotide and Plavix® Treatment Results in Enhanced Antithrombotic Activity without Increased Risk of Bleeding in Mouse Models of Thrombosis. (2009) (0)
- Changing the raf gene expression with antisense oligonucleotides (1996) (0)
- 9th annual meeting of the Oligonucleotide Therapeutics Society Naples, Italy | October 6-8, 2013. Session summaries. (2013) (0)
- P1.3: A NEW DYNAMIC ORGAN BATH SETUP TO ASSESS ISOBARIC STIFFNESS PARAMETERS OF PERIODICALLY STRETCHED ISOLATED MOUSE AORTIC SEGMENTS (0)
- Antithrombotic Effects of a FXI Antisense Oligonucleotide in Mice (2008) (0)
- METHOXYETHYL MODIFICATION IMPROVES INHIBITORY EFFECT OF C-RAF ANTISENSE OLIGODEOXYNUCLEOTIDES IN VITRO AND IN VIVO (1999) (0)
- Development of ISIS-TTRRx for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) (S34.009) (2015) (0)
- Platelet-localized FXI promotes a glycoprotein Ibα dependent feedback loop in arterial hypertension and vascular inflammation (2015) (0)
- thrombosis in mice without increased risk of bleeding Selective depletion of plasma prekallikrein or coagulation factor XII inhibits (2012) (0)
- Repeated intravitreal injection of an anti-C-raf kinase antisense oligonucleotide in a pig model of branch retinal vein occlusion Tolerability and efficacy (2001) (0)
- Identification and Characterization of Mouse Antisense Oligonucleotides (ASOs) Directed at Rhodopsin (2013) (0)
- MODULATION OLIGONUCLEOTIDIQUE ANTISENS DE L'EXPRESSION DU GENE raf (1995) (0)
- Date of Patent : ( 54 ) ANTISENSE INHIBITION OF MEKK 2 EXPRESSION ( 75 ) Inventors : (2017) (0)
- Broken 2'-modified oligonucleotides (1992) (0)
- Unveiling a Critical Role of Thrombin in Enhanced CD8+ T Cell Response to Cancer (2019) (0)
- Antisense Oligonucletide Mediated Depletion of Factor VII Provides Protection from Ferric Chloride Induced Thrombosis without Increased Bleeding Risk in Mice (2008) (0)
- Protection of Human Factor V from Activated Protein C Using a Monoclonal Antibody-Biochemical Characterization and Evaluation Using a Mouse Injury Model (2021) (0)
- Selective Abrogation of STAT5 Expression Impairs the Proliferation of Acute Myeloid Leukemia Cells with Various Cytogenetic Alterations (2008) (0)
- Identification of a Human Clinical Candidate ASO Selectively Targeting the P23H Variant of Rhodopsin for the Treatment of P23H Rhodopsin-mediated ADRP (2015) (0)
- Abstract PR12: Discovery and preclinical evaluation of cEt-modified KRAS antisense oligonucleotide inhibitors (2015) (0)
- Abstract 12908: Inhibition of Hepatic Sulf2 in vivo Corrects Postprandial Dyslipidemia in Type 2 Diabetic Mice (2011) (0)
- Reversibility in Mice of FXI Antisense-Induced Anticoagulation by Administration of FXI Protein Concentrate or a Sense Oligonucleotide. (2008) (0)
- Sugar modified oligonucleotides gapped (1997) (0)
- Modulation factor expression 11 (2009) (0)
- Antisense Oligonucleotide Mediated Depletion of Factor XI Prevents Vascular Occlusion in An Experimental Thrombosis Model in Primates (2011) (0)
- Abstract B197: Selective depletion of YAP1 with next-generation antisense oligonucleotides leads to immune cell infiltration and tumor regression in mouse models of HCC (2018) (0)
- Antisense therapy targeting complement factor B (2018) (0)
- Antisense Oligonucleotide Targeting of Thrombopoietin Synthesis Reduces Platelet Count within the Hemostatic Range and Slows Progression of De Novo Mammary Carcinogenesis in the Mmtv-Pymt Mouse (2018) (0)
- Preclinical Development Transcription Factor Stat 5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo (2011) (0)
- Abstract 2951: Potent antisense pharmacology of highly optimized antisense oligonucleotides in multiple transgenic, spontaneous and patient derived xenograft models of cancer reveals antitumor activity for the non-coding RNA MALAT-1. (2012) (0)
- Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML. (2004) (0)
- 321 ANTISENSE INHIBITOR TARGETING FULL LENGTH ANDROGEN RECEPTOR AND ITS SPLICE VARIANTS SUPPRESSES MDV3100 RESISTANT PROSTATE CANCER CELL GROWTH (2013) (0)
- Antisense modulation of clusterinexpression (2001) (0)
- Evaluation of the Antihemostatic and Antithrombotic Effects of Lowering Coagulation Factor VII Levels in a Non-human Primate (2020) (0)
- Inhibition of Cell Growth by Antisense Oligonucleotides Targeting the Growth-Related Protein Kinase c-raf. (2000) (0)
- A Role for Antisense Technology in the Discovery of Highly Specific and Versatile Signal Transduction Inhibitors (2001) (0)
- Nicotinamide N-methyltransferase is a novel regulator of energy metabolism in adipose tissue (2014) (0)
- TARGETING INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR WITH ANTISENSE OLIGONUCLEOTIDES IN PROSTATE CANCER (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Brett P. Monia?
Brett P. Monia is affiliated with the following schools:
